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Amyloid-b (Ab) peptides are implicated in the causation of memory loss, neu-
ronal impairment, and neurodegeneration in Alzheimer’s disease. Our recent
work revealed that Ab 1–42 and Ab 25–35 inhibit long-term memory (LTM)
recall in Lymnaea stagnalis (pond snail) in the absence of cell death. Here,
we report the characterization of the active species prepared under different
conditions, describe which Ab species is present in brain tissue during the
behavioral recall time point and relate the sequence and structure of the oli-
gomeric species to the resulting neuronal properties and effect on LTM. Our
results suggest that oligomers are the key toxic Ab1–42 structures, which
likely affect LTM through synaptic plasticity pathways, and that Ab 1–42
and Ab 25–35 cannot be used as interchangeable peptides.
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Amyloid b (Ab) is cleaved from the amyloid precursor
protein (APP) to produce a range of Ab isoforms of
which Ab 1–40 and Ab 1–42 are the most common.
This APP cleavage process is well-defined, with Ab
peptides predominantly being produced via ɑ- or b-
and ɣ-secretases [1,2]. Alongside Ab peptides, other
APP fragments are produced in the cleavage process
and are believed to play neuroprotective and neu-
rotrophic roles in the brain [1,2]. The function of APP
and its peptides are unknown, but appear to have an
important role in neuromuscular junction formation,
synaptic transmission, and ion channel function [3]. In
Alzheimer’s disease (AD), the shift from healthy pro-
tective function to pathogenic cell death arises from an
increase in Ab 1–42 production and oligomerization
[1,4,5]. Other Ab peptides of various lengths have also
been found in both AD brains and cerebrospinal fluid
[6,7], being produced via caspases and proteolytic
degrading enzymes [1]. These fragments have been sug-
gested to play an important role in pathology [1].
One of these shorter fragments, Ab 25–35, has been
detected in AD plaques and is a known cleavage pro-
duct of Ab 1–40 racemized at D-Ser26 [8]. Ab 25–35
may represent the toxic core of the more
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physiologically prevalent toxic species Ab 1–42 [9], and
it displays similar fibrillization through b sheet forma-
tion [10]. For this reason, many labs utilize Ab 25–35 as
a cost-effective means of studying Ab. Of the different
length peptides, available both synthetically and in AD-
related tissues, it is generally agreed that these peptides
are toxic when they exist as small, prefibrillar oligomers
[11–15]. Specifically, dimers and dodecamers have been
directly linked to toxicity and behavioral disruptions
[12,13,16–18], although others suggest that all soluble
low-n oligomers could be toxic [19,20]. These toxic oli-
gomers produce AD pathology by first disrupting
synapse function in memory-encoded neuronal circuitry,
further developing into synaptic degeneration, and
finally full cell death [12,13,21].
Amyloid precursor protein is highly evolutionarily
conserved, with > 95% sequence homology existing
across mammalian species and high homology within
invertebrate species [22,23]. Many invertebrate model
organisms have been used for Ab and AD studies
[24,25]. For example, Drosophila has an APP ortholog,
APPL [26], an ɑ-secretase ortholog [27], and compo-
nents of ɣ-secretase [28–30]. This ɣ-secretase can process
human APP [31,32] and human APP can be cleaved to
produce Ab in flies, suggesting an endogenous b-secre-
tase-like protease in Drosophila [32]. APP and the pro-
tease processing system (presenilin 1 and 2) are well
conserved across the animal kingdom and APP mRNA
expression has been shown in the ganglia of Apylsia cal-
ifornica [33], which is closely related to Lymnaea.
Ab and AD research has only rarely branched into
molluscan model systems, although these offer a
wealth of information on cellular and molecular mech-
anisms of memory function and dysfunction by pro-
viding uniquely tractable models in the field [34].
Indeed, the use of mollusks such as the sea slug A. cal-
ifornica and the pond snail Lymnaea stagnalis helped
build much of the molecular and electrophysiological
understanding of learning and memory [34–40]. The
first group to utilize a mollusk in Ab memory studies
considered Ab 25–35 in the land snail Helix lucorum
[41]. In these experiments, the researchers reported
that the animals’ conditioned food aversion reflex was
inhibited when Ab was administered before training
[41]. Our lab expanded the Ab studies in mollusks,
finding that Ab 1–42 and Ab 25–35 disrupted consoli-
dated long-term memory (LTM) in the pond snail
L. stagnalis [42].
Our studies brought about a very intriguing ques-
tion: Are the two peptides affecting memory consolida-
tion via similar pathways? Although both peptides
ultimately disrupted consolidated long-term memory
prior to neuronal death, there were significant
differences in: (a) peptide production, (b) morphology,
(c) quantity of oligomers in the hemolymph, and (d)
effects on neuron electrical properties.
1 Firstly, although Ab 1–42 and Ab 25–35 both dis-
rupted consolidated long-term memory, the two pep-
tides were produced under very different conditions
[42]. Ab 1–42 was administered at 1 lM directly into
the hemolymph, with an expected final concentration
of 1 nM. Moreover, Ab 1–42 was solvent prepared.
In this preparation method, the lyophilized peptide is
solubilized in a fluorinated alcohol for disaggrega-
tion, dried, and resolubilized in DMSO. The solubi-
lized peptide then undergoes removal of solvent via a
desalting column and buffer-exchange into a final
normal saline solution, and is centrifuged to remove
any insoluble aggregates. This solvent preparation
method (see Materials and methods) has been well
studied [42–44] and produces maximal soluble Ab 1–
42. In contrast, lyophilized Ab 25–35 was solubilized
directly into saline solution (as for H. lucorum [41]),
incubated for 2 h at room temperature, and then
administered at 0.1 mM with an expected final con-
centration of 0.1 lM [42]. When injected at 1 lM,
memory was no longer disrupted which suggests that
a significantly higher concentration of Ab 25–35 was
necessary for similar behavioral effects [42].
2 Comparison of the morphological features of Ab 1–
42 and Ab 25–35 peptides over a 24-h in vitro
assembly by transmission electron microscopy
(TEM) revealed significant differences between the
structures formed by the two peptides under these
conditions. Ab 1–42 followed a self-assembly path-
way from oligomeric, to protofibrillar, and finally
fibrillar states while Ab 25–35 was predominantly
crystalline in morphology and aggregated further
over time [42].
3 Hemolymph of both Ab 1–42- and Ab 25–35-treated
animals underwent formic acid extraction, immuno-
gold labeling with Ab oligomer antibody Nu1 [12],
and were visualized with TEM. Both samples con-
tained more Ab oligomer labeling than buffer-trea-
ted controls, but with a 600-fold more labeling in
Ab 1–42-treated animals compared to Ab 25–35
[42].
4 Finally, the two peptides disrupted properties of the
Lymnaea nervous system differently. Ab 25–35
caused a decrease in input resistance and an aboli-
tion of the learning-induced depolarization of the
membrane potential of the cerebral giant cell
(CGC), a key neuron underlying memory [45,46],
while Ab 1–42 had no detectable effect on CGC
electrical properties [42].
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These findings led us to consider whether the
observed behavioral and electrophysiological differ-
ences in the Ab peptides are due to the different
lengths and sequences of the peptides, or to the struc-
ture the peptides adopted by the 24-h postinjection
time point when the memory test was conducted. If
the primary structure is the critical difference between
the two peptides, the method of preparation should
not alter the peptide’s effect on behavior or electro-
physiology. However, if the peptide’s effect on behav-
ior is related to its structure at the 24-h postinjection
time point, then a difference in peptide preparation
should have drastic effects on the resulting behavior
and electrophysiology. To address these questions, we
prepared Ab 25–35 using the previously mentioned sol-
vent preparation method [44], and report the resulting
changes in LTM, electrical neuronal properties, pep-
tide morphology, and quantity of oligomers in the
hemolymph after 24 h of in vivo incubation. Here, we
reveal significant differences in the effects of peptides
formed under different conditions and with different
structures; expanding knowledge of the effects of oli-
gomeric Ab on memory and cellular functions in the
brain.
Materials and methods
Experimental animals
Pond snails, L. stagnalis, were bred and maintained in 18–
22 °C copper-free water in large holding tanks, with a
12 : 12 h light–dark cycle. The animals were fed twice a
week with Tetra-Phyll (TETRA Werke, Melle, Germany)
and with lettuce three times a week. Three days before each
experiment an appropriate number of animals were trans-
ferred into the behavioral laboratory where they were kept
in smaller tanks in a food-deprived state before the experi-
ments commenced.
Preparation and systemic application of Ab
peptides
Ab peptides were solvent prepared, as described previously
[42,44]. Briefly, 0.2 mg Ab Fragment 25–35 (Sigma-Aldrich,
Irvine, UK) or Ab 1–42 (rPeptide; Bogard, GA, USA) were
solubilized in hexafluoroisopropanol (HFIP; Sigma-
Aldrich) to disaggregate the peptides, and then dried com-
pletely to remove HFIP. This protocol has been optimized
[43] and has been shown to reproducibly produce soluble,
oligomeric Ab 1–42 [42,44,47]. Once HFIP was completely
evaporated, dry DMSO (Sigma-Aldrich) was added to the
Ab. The Ab was then added to a prepared Zeba buffer-
exchange column (ThermoFisher Scientific, Paisley, UK)
with a normal saline solution (50 mM NaCl, 1.6 mM KCl,
2 mM MgCl2. 6H2O, 3.5 mM CaCl2 9 2H2O, 10 mM
HEPES [4-(2-hydroxyethyl)-1-piperazine- ethanesulfonic
acid], pH 7.9) [48] stack and centrifuged for 30 min at
16 000 g, 4 °C to remove insoluble structures and all
remaining solvents [49]. This final step is critical for remov-
ing fibrillar species, leaving only soluble, oligomeric Ab
[44]. Protein concentration was calculated by measuring
optical density at 280 nm using a NanoDrop spectropho-
tometer (Thermo Fisher, Paisley, UK) and correcting for
the molar absorption coefficient of each peptide. Ab pep-
tides were then diluted to the 1 lM working concentration
in 100 lL using normal saline solution at 20 °C, and were
systemically injected into the animals directly after prepara-
tion using a 1-mL syringe with 30-gauge precision glide
needles (Becton Dickinson, Oxford, UK). For vehicle con-
trol animals, 100 lL of normal saline solution was injected.
Formic acid-extracted hemolymph preparation
After 24 h in vivo incubation of solvent-prepared Ab 25–35,
roughly 1 mL of hemolymph was extracted from each snail
and submitted to formic acid extraction, as described previ-
ously [42,50]. Briefly, the hemolymph was mixed with equal
volumes 0.4% diethylamine/100 mM NaCl. About 400 lL
was then centrifuged at 16 000 g for 1 h, 4 °C. Supernatant
was aspirated and 200 lL 1 M Tris pH 7.4 was added to the
pellet. Four hundred microliters of cold formic acid was
added and the sample was sonicated and then centrifuged at
16 000 g for 1 h, 4 °C. The supernatant was neutralized in
4 mL 1 M Tris, 0.5 M Na2HP04, which was again cen-
trifuged at 16 000 g for 1 h, 4 °C. The supernatant was neu-
tralized with 1/10 volume 1 M Tris, pH 6.8. The samples
were stored at 80 °C until used for imaging by TEM.
Transmission Electron Microscopy
As previously described [42], 4 lL of the formic acid-
extracted hemolymph sample was pipetted on to Formvar/
carbon coated 400-mesh copper grids (Agar Scientific,
Essex, UK), washed with Milli-Q water (EMD Millipore,
Watson, UK), and negative stained with 2% uranyl acetate
for 1 min. Grids were allowed to air dry. After initial imag-
ing the samples were immunogold labeled with 1 lgmL1
Nu1 (Klein Laboratory) [12], a mouse conformational anti-
body raised against oligomeric Ab, and then labeled with
goat anti-mouse 10 nm gold-conjugated secondary anti-
body (BBI Solutions OEM Ltd., Cardiff, UK) to label oli-
gomeric structures. All grids were examined in a Hitachi
7100 TEM at 100 kV and digital images acquired with an
axially mounted (2K 9 2K pixel) Gatan Ultrascan 1000
CCD camera (Gatan UK, Oxford, UK).
Negative staining of solvent-prepared Ab 25–35 was used
to monitor peptide morphology over the incubation time.
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Aliquots of 100 lM Ab 25–35 were allowed to incubate in
normal saline solution (50 mM NaCl, 1.6 mM KCl, 2 mM
MgCl2 9 6H2O, 3.5 mM CaCl2 9 2H2O, 10 mM HEPES,
pH 7.9 at 20 °C) in a closed Eppendorf tube for 0, 3, or
24 h. This in vitro incubation method previously produced
reliable and reproducible results for buffer-prepared Ab
25–35 and solvent-prepared Ab 1–42 [42]. Samples were
prepared and images acquired as stated above. This experi-
ment was conducted three times, to ensure assembly was
consistent.
Single-trial food-reward classical (CS+US)
conditioning
Using well-established methods [45], L. stagnalis underwent
single-trial food-reward classical conditioning in which the
conditioned stimulus (amyl acetate) and the unconditioned
stimulus (sucrose) were paired. An unpaired control was
not used, as naive controls show no difference from
unpaired controls behaviorally [51,52] or electrophysiologi-
cally [53]. Both the vehicle-injected control and Ab-injected
groups were trained. The na€ıve groups were not trained
and were not injected, but underwent the same food-depri-
vation/feeding schedule and handling as the experimental
groups.
Electrophysiology
The two-electrode current-clamp-based electrophysiology
method employed to test the electrical properties of the
CGCs has been described in detail elsewhere [45]. Briefly,
the cerebral ganglia (location of the CGCs) were
desheathed and treated with a solid protease (Sigma type
XIV; Sigma-Aldrich) to soften the inner sheath for intracel-
lular recording. Sharp electrodes (5–20 MΩ) were filled
with 4 M potassium acetate. Signals from the intracellular
electrodes were amplified using Axoclamp 2B (Axon
Instrument, Molecular Devices, Sunnyvale, CA, USA) and
NL 102 (Digitimer, Hertfordshire, UK) amplifiers and digi-
tized at 2 kHz using a micro 1401 Mk II interface and
analyzed using SPIKE 2 software (version 5.21; Cambridge
Electronics Design, Cambridge, UK). The CGC membrane
potential and input resistance as well as action potential
characteristics (frequency, amplitude, half-width, and after-
hyperpolarization amplitude) were analyzed over a 100-s
period recorded 120 s after the initial electrode impale-
ment. This is sufficient time to allow the cell to recover
from impalement [45,53,54].
Statistical analysis
Data were analyzed using GRAPHPAD PRISM software (version
4.03; GraphPad Software Inc., San Diego, CA, USA). Nor-
mality was tested using D’Agostino and Pearson omnibus
normality test. Data were first analyzed with one-way
ANOVA followed by Tukey’s multiple comparison to
establish significance (criterion, P < 0.05).
Results
Solvent-prepared Ab 25–35 has no significant
effect on Lymnaea LTM recall or electrical
neuronal properties
Two important questions in the Ab and AD field still
demand elucidation: (a) Can synthetic Ab 25–35 reli-
ably be used in place of synthetic Ab 1–42?; (b) Are
the observed behavioral effects of various Ab peptides
on consolidated long-term memory due to different
primary structures, or due to the final conformation of
these peptides? We speculated briefly about the
answers to these questions previously after we discov-
ered that both Ab 1–42 and Ab 25–35 disrupted con-
solidated LTM in Lymnaea at different concentrations
and potentially via different pathways [42]. Here, we
aim to directly address each question by comparing
synthetic peptide preparation methods and observing
the resulting effect on behavior. For solvent-prepared
Ab, peptides are solubilized in HFIP and undergo col-
umn purification and centrifugation to remove aggre-
gated species. This method produces soluble Ab
[42,44,47], which is then diluted into normal saline.
Previously, buffer-prepared Ab peptides had been solu-
bilized in normal saline and vortexed briefly [41,42].
To tackle these questions, we used a single-injection
and single-trial behavioral paradigm in a tractable ani-
mal model of long-term memory. Lymnaea stagnalis
were trained using single-trial food-reward classical
conditioning [45], injected with 1 lM solvent-prepared
Ab 25–35 or Ab 1–42 24 h post-training, and tested
48 h post-training (Fig. 1A). Ab-treated animals were
compared to vehicle-treated control animals and na€ıve
animals, shown in Fig. 1. Ab 25–35 (1 lM) did not
cause behavioral deficits; instead, the animals in Ab
25–35 (1 lM) group exhibited similar behavioral
responses to vehicle-injected control animals. Both Ab
25–35 (1 lM)-treated and vehicle-injected animals
exhibited a significantly greater feeding response to the
conditioned stimulus compared to naive and Ab 1–42
(1 lM)-treated animals (Fig. 1B). Thus, solvent-pre-
pared Ab 25–35 (1 lM) does not disrupt memory in
contrast to solvent-prepared Ab 1–42 (1 lM), when
applied at equal concentrations.
We continued our investigation to determine
whether solvent-prepared Ab 25–35 could alter spike
characteristics and two of the key electrical properties
of the CGCs, membrane potential and membrane
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resistance, both of which were shown to be affected by
buffer-prepared Ab 25–35 [42]. Of the measured
parameters, learning-induced depolarization of the
CGC soma membrane was linked to long-term mem-
ory in previous studies [46] with the other parameters
remaining unaffected by single-trial classical condition-
ing [45]. The hypothesis we were testing here was that
the solvent-prepared Ab 25–35’s inability to disrupt
memory was predominantly due to a lack of effect on
the CGC’s membrane potential. The other parameters
were measured because it could not be ruled out that
similar to its buffer-prepared version, solvent-prepared
Ab 25–35 would abolish learning-induced depolariza-
tion of the CGC soma membrane but the memory
impairing effects of this change would be compensated
for by homeostatic changes in spike characteristics or
input resistance. In accordance with previous findings
[45], no change was observed in key parameters of the
CGC action potentials, such as spike frequency, ampli-
tude, half-width, or after-hyperpolarization after classi-
cal conditioning (Fig. S1). The input resistance of the
CGC soma membrane was also unaffected by solvent-
prepared Ab 25–35 (Fig. 2). Importantly, the CGC’s
membrane potential remained depolarized, similar to
vehicle controls (Fig. 2).
Characterization of solvent-prepared Ab 25–35
From the combined behavioral and electrophysiologi-
cal experiments from Figs 1 and 2, we were very curi-
ous to understand the conformation and state of
oligomerization of the apparently benign, solvent-pre-
pared Ab 25–35. We predict that by altering the
method of peptide preparation from buffer prepared
[41,42] to solvent prepared, the conformational state
of Ab 25–35 has been altered and this has affected Ab
25–35’s ability to disrupt nonsynaptic plasticity in
Lymnaea central nervous system and LTM [42,45]. An
intriguing point is thus raised: a simple alteration of
peptide preparation, and thus conformation of the
protein, is directly related to its function. We contin-
ued our investigation into this benign Ab 25–35 to
understand what morphological change occurred as a
result of solvent preparation.
Ab 1–42 self-assembles from soluble monomer, to
soluble low-n oligomers and large-n oligomers, and
finally to cross-b fibrils [9]. Along this pathway, mor-
phologically distinct oligomeric, protofibrillar, and fib-
rillar states can be observed using negative stain TEM.
To investigate the assembly of the solvent-prepared Ab
25–35, the peptide was allowed to assemble in vitro at
room temperature in a closed Eppendorf tube over a
24-h period and samples were examined by TEM after
0, 3, and 24 h of incubation. There were no observable
species at either the 0- or 3-h time points, suggesting
the peptide remains in an unassembled or low-n oligo-
meric state. Due to negative stain method constraints, a
resolution limit of about 3 nm exists [54]. Therefore, it
is unlikely that a monomer or low-n oligomer of Ab
25–35 structure can be visualized using this method. By
24 h, amyloid-like fibrils had formed (Fig. 3). These
fibrils have a pronounced curved appearance. There
was no evidence of higher order oligomer formation at
any observed time point (Fig. 3A,B).
The resolution limitations of negative stain may be
the reason why no oligomeric species were observed.
To examine whether oligomeric Ab 25–35 is found
in vivo following administration of solvent preparation
samples, Ab 25–35 was extracted from the animals’
hemolymph 24 h after treatment using formic acid and
prepared for immunogold labeling and imaging using
TEM [50]. Soluble fractions were added to a TEM
grid, negative stained, immunogold labeled using the
anti-Ab oligomer antibody Nu1 [12] and a gold-conju-
gated secondary antibody, and imaged using TEM.
Fig. 1. Solvent-prepared Ab 25–35 (1 lM) does not cause memory
impairment when allowed to incubate in vivo for 24 h. (A) Timeline
of the experiment. CS, conditioned stimulus; US, unconditioned
stimulus. (B) Four starved animal groups [solvent prepared Ab 25–
35 (n = 23) and Ab 1–42 (n = 13), buffer-only vehicle (n = 18),
na€ıve (untreated and untrained) (n = 17)] were tested for rasp rate
to amyl acetate, a measure of the feeding response to the
conditioned stimulus. Means  standard error mean (SEM) values
are shown. Asterisks indicate behavioral responses that are
significantly different between groups. ANOVA, P < 0.0001.
Tukey’s multiple comparisons with P < 0.05: Ab 25–35 vs. Na€ıve,
Ab 25–35 vs. Ab 1–42, Vehicle vs. Na€ıve, Vehicle vs. Ab 1–42.
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Even if the oligomers are too small for visualization
by TEM, the antibody gold particles will indicate areas
where Ab 25–35 oligomers are present. Extracts from
animals treated with solvent-prepared Ab 25–35
expressed negligible labeling, less than 1 gold label per
micrograph (Fig. 4A). This was similar to the vehicle-
injected (buffer only) animal oligomer levels (Fig. 4B).
Ab 1–42-injected positive controls labeled very well
with this immunogold-labeling method (Fig. 4C) and
the Nu1 antibody was validated by a lack of labeling
Fig. 2. Electrophysiological effects of
solvent-prepared Ab 25–35 treatment. (A)
Examples of electrophysiological
recordings of CGC membrane potential
and tonic firing activity under control and
experimental conditions. (B) Membrane
potential, represented graphically [vehicle/
buffer control (n = 12); Ab 25–35 (n = 10);
na€ıve (n = 12)]. Means  SEM values are
shown. One-way ANOVA, P = 0.0052.
Tukey’s tests with P < 0.05: Vehicle vs.
Na€ıve, Ab 25–35 vs. Na€ıve (indicated by
asterisks). (C) Examples of
electrophysiological recordings of CGC
membrane resistance under control and
experimental conditions. (D) Membrane
resistance, represented graphically
[vehicle/buffer control (n = 11); Ab 25–35
(n = 10); na€ıve (n = 11)]. Means  SEM
values are shown. One-way ANOVA,
P = 0.3217.
A B C
Fig. 3. Solvent-prepared Ab 25–35 fibrilizes when allowed to incubate in normal saline solution for 24 h. About 100 lM solvent-prepared Ab
25–35 was prepared as described in Materials and methods and allowed to aggregate in normal saline solution over a 24-h period. Samples
were taken at 0, 3, and 24 h, negative stained, and imaged using the TEM. The peptide self-assembles over the 24-h period. (A) No
observable Ab 25–35 species are found at the 0-h time point. (B) No observable Ab 25–35 species are found at the 3-h time point. (C) Ab
25–35 fibrils are found at the 24-h time point. Scale bars represent 100 nm.
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in the secondary antibody-only method control
(Fig. 4D). The only sample with significant immuno-
gold labeling was the positive control (Fig. 4). This
suggests that nonspecific antibody labeling was very
low and that oligomeric Ab 25–35 species were not
present at detectable levels in the sample extracted
from treated animals.
Discussion
Solubilized Ab peptides are commonly used in amyloid
studies. Ab 1–42 is the predominant toxic species, as it
has been linked to AD and the accompanying memory
loss and neuronal death [9]. However, Ab 25–35 is still
commonly utilized as an affordable alternative to Ab
1–42, as it has been shown to be toxic to cells and
retains similar structural properties [1,6–10]. Much
focus has gone into appropriate preparation of Ab
peptides, and standardization of peptide preparation
will likely decrease experimental variability between
research groups. This research is critical, as varying
the preparation of synthetic peptides is known to
result in morphologically and functionally distinct Ab
[50,55,56]. We intended to study the effect of this vari-
ability in Ab peptide preparation by comparing previ-
ously published work on solvent-prepared Ab 1–42
and buffer-prepared Ab 25–35, with our current work
on solvent-prepared Ab 25–35. The effect of Ab prepa-
ration on downstream memory mechanisms remains
unclear. Here, we considered how Ab preparation
using solvent affects the range of conformational spe-
cies produced and their effects on a highly tractable
model animal. We considered Ab’s effect on Lymnaea
LTM, a number of electrical properties of a key neu-
ron in Lymnaea’s central nervous system, the presence
of oligomers in Lymnaea hemolymph, and the pep-
tide’s morphological change over time in vitro. This
work not only identifies preparation methods of
A
E
B C D
Fig. 4. Oligomeric Ab is not found in the hemolymph of animals after 24 h in vivo incubation with solvent-prepared Ab 25–35. (A)
Micrograph of negative stained and Nu1 immunogold-labeled, formic acid-extracted hemolymph from animals treated with 1 lM solvent-
prepared Ab 25–35 after 24 h in vivo incubation. (B) Micrograph of negative-stained and Nu1 immunogold-labeled, formic acid-extracted
hemolymph from animals treated with vehicle after 24 h in vivo incubation. (C) Positive control: Micrograph of negative stained and Nu1
immunogold-labeled, formic acid-extracted hemolymph from animals treated with 1 lM solvent-prepared Ab 1–42 after 24 h in vivo
incubation. Red circles indicate gold particles. (D) Method control: Micrograph of negative stained and secondary antibody-only labeled,
formic acid-extracted hemolymph from animals treated with 1 lM solvent-prepared Ab 1–42 after 24 h in vivo incubation. Scale bars in A–D
represent 100 nm. (E) Graphical representation of immunogold labels present in micrographs. Ab 25–35 n = 20, Vehicle n = 16, positive
control n = 11, antibody control n = 16. Means  SEM values are shown. Asterisk indicates significant differences in gold particles per
image between the positive control and each of the other groups (One-way ANOVA, P < 0.0001; Tukey’s, P < 0.05).
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functionally relevant Ab 1–42 and Ab 25–35, but may
indicate that care should be taken when replacing Ab
1–42 with Ab 25–35. Indeed, the two peptides have
drastically differing effects on Lymnaea behavior and
nonsynaptic plasticity when prepared and applied
under memory-disrupting conditions and concentra-
tions.
We observed here and in previous work that
memory recall 24 h postinjection, 48 h post-training
is only disrupted in Ab-treated animals that retain
oligomeric species in their hemolymph after 24 h
in vivo incubation [42]. This is unsurprising, as other
labs have suggested that the solvent used to dissolve
synthetic Ab affects the initial conformation and
aggregation kinetics [57]. Importantly, the difference
in primary structure of Ab 1–42 and Ab 25–35 dras-
tically alters how these peptides fold in different
environments, as revealed by TEM studies by com-
paring solvent-prepared Ab 1–42 and Ab 25–35 with
buffer-prepared Ab 25–35 [42]. This emphasis on
environmental influence is critical to AD research, as
Ab of varying lengths have been identified in the
disease [6,7]. The research presented here suggests
that the formation of intermediates by Ab peptides
is heavily influenced by preparation method, and
when Ab 25–35 is solvent prepared, it does not form
pathological species. Only when prepared to form
nonamyloid-like crystalline structures does Ab 25–35
have the pathologically relevant effect of impairing
LTM [42].
Importantly, only specific phases of memory seem
to be vulnerable to Ab oligomers in these studies.
We found that the 24–48-h postconditioning time
point is vulnerable to Ab oligomers [42]. This time
point is not vulnerable to Ab nonoligomeric species
[42]. The 0–24 h post-training time point is also not
disrupted by Ab treatment (Fig. 5), regardless of
whether oligomeric species are present or not [42].
This supports previous studies that showed that Ab
oligomers are the memory-disrupting species
[13,14,16,18] and research that suggests that memory
phases dependent upon synapse structure remodeling
are vulnerable to Ab [55,58,59]. Our work supports
the emerging hypothesis that oligomeric Ab affects
memory by altering new synaptic growth or synaptic
rearrangement [60] (Fig. 5), which is necessary for
the persistence of long-term memory [61]. Our explo-
ration of structure-dependent effects of Ab on
behavioral function critically enhances the field in a
novel way. Due to the nonamyloid-like crystalliza-
tion of memory-disrupting Ab 25–35, we believe this
could be an artifact of improperly folded peptide,
which can then disrupt the electrical properties of
neurons in a non-native way. However, further
Fig. 5. Behavioral memory time lines. (A) 24-h in vivo incubation, memory recall time point with Ab treatments that result in the presence
of in vivo oligomers after 24 h. Memory is inhibited. (B) 24-h in vivo incubation, memory recall time point with Ab treatments that exhibit no
in vivo oligomers after 24 h. Memory functions correctly. (C) 24-h in vivo incubation, memory acquisition time point with Ab treatments that
result in the presence of in vivo oligomers after 24 h. Memory functions correctly. (D) 48-h in vivo incubation, memory acquisition time
point with Ab treatments that result in the presence of in vivo oligomers after 24 h. Memory is inhibited. The red ‘9’ indicates experiments
where memory is inhibited. The green ‘check’ indicates experiments where memory functions correctly. The pink line indicates the 24–48-h
postconditioning time point that may be vulnerable to Ab oligomers.
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experiments are needed to be certain. This in-depth
focus of Ab structure, and its influence on neuronal
circuitry and memory time points, narrows the scope
for future studies investigating molecular memory
and drug targeting.
Acknowledgements
We thank Julian R. Thorpe, Thomas L. Williams,
Souvik Naskar, and Catherine Smith for their valuable
help. This work was supported by the MRC (MR/
K022105/1), BBSRC (BB/H009906/1), Alzheimer’s
Society, Alzheimer’s Research UK and the American
Friends of the University of Sussex. We gratefully
acknowledge the generous donation of Nu1 antibody
by the group of Prof William Klein, Northwestern
University, USA.
Author contributions
LF, GK, and LCS conceived the project. LF and LCS
designed the imaging experiments, which were per-
formed by LF and DV, and analyzed by LF. LF
designed, performed, and analyzed the behavioral
experiments. LF and MC designed the electrophysiol-
ogy experiments, which were performed and analyzed
by MC. LF, GK, and LCS wrote the paper and all
authors edited the manuscript.
Data sharing statement
The datasets supporting the conclusions of this article
are included within the article and its supporting infor-
mation.
References
1 Kaminsky YG, Marlatt MW, Smith MA and Kosenko
EA (2010) Subcellular and metabolic examination of
amyloid-beta peptides in Alzheimer disease
pathogenesis: evidence for A beta (25–35). Exp Neurol
221, 26–37.
2 Walsh DM and Selkoe DJ (2007) A beta oligomers –
a decade of discovery. J Neurochem 101,
1172–1184.
3 Hoe HS, Lee HK and Pak DTS (2012) The upside of
APP at synapses. CNS Neurosci Ther 18, 47–56.
4 Gong YS, Chang L, Viola KL, Lacor PN, Lambert
MP, Finch CE, Krafft GA and Klein WL (2003)
Alzheimer’s disease-affected brain: presence of
oligomeric A beta ligands (ADDLs) suggests a
molecular basis for reversible memory loss. Proc Natl
Acad Sci USA 100, 10417–10422.
5 Shankar GM, Li S, Mehta TH, Garcia-Munoz A,
Shepardson NE, Smith I, Brett FM, Farrell MA,
Rowan MJ, Lemere CA et al. (2008) Amyloid-beta
protein dimers isolated directly from Alzheimer’s brains
impair synaptic plasticity and memory. Nat Med 14,
837–842.
6 Naylor R, Hill AF and Barnham KJ (2008)
Neurotoxicity in Alzheimer’s disease: is covalently
crosslinked A beta responsible? Eur Biophys J 37, 265–
268.
7 Maddalena AS, Papassotiropoulos A, Gonzalez-Agosti
C, Signorell A, Hegi T, Pasch T, Nitsch RM and Hock
C (2004) Cerebrospinal fluid profile of Amyloid beta
peptides in patients with Alzheimer’s disease determined
by protein biochip technology. Neurodegener Dis 1,
231–235.
8 Kubo T, Nishimura S, Kumagae Y and Kaneko I
(2002) In vivo conversion of racemized beta-amyloid (D-
Ser(26) A beta 1–40) to truncated and toxic fragments
(D-Ser(26) A beta 25–35/40) and fragment presence in
the brains of Alzheimer’s patients. J Neurosci Res 70,
474–483.
9 Cardenas-Aguayo MC, Silva-Lucero MC, Cortes-Ortiz
M, Jimenez-Ramos B, Gomez-Virgilio L, Ramirez-
Rodriguez G, Vera-Arroyo E, Fiorentino-Perez R,
Garcia U, Luna-Munoz J et al. (2014) Physiological
role of amyloid beta in neural cells: the cellular trophic
activity, Chapter 9. In Neuroschemistry (Heinbockel T,
ed.). InTech, Mexico City.
10 Naldi M, Fiori J, Pistolozzi M, Drake AF, Bertucci C,
Wu R, Mlynarczyk K, Filipek S, De Simone A and
Andrisano V (2012) Amyloid b-peptide 25–35 self-
assembly and its inhibition: a model undecapeptide
system to gain atomistic and secondary structure details
of the Alzheimer’s disease process and treatment. ACS
Chem Neurosci 3, 952–962.
11 Oda T, Pasinetti GM, Osterburg HH, Anderson C,
Johnson SA and Finch CE (1994) Purification and
characterization of brain clusterin. Biochem Biophys Res
Commun 204, 1131–1136.
12 Lambert MP, Barlow AK, Chromy BA, Edwards C,
Freed R, Liosatos M, Morgan TE, Rozocsky I,
Trommer B, Viola KL et al. (1998) Diffusible,
nonfibrillar ligands derived from A beta(1-42) are
potent central nervous system neurotoxins. Proc Natl
Acad Sci USA 95, 6448–6453.
13 Walsh DM, Klyubin I, Fadeeva JV, Cullen WK,
Anwyl R, Wolfe MS, Rowan MJ and Selkoe DJ
(2002) Naturally secreted oligomers of amyloid beta
protein potently inhibit hippocampal long-term
potentiation in vivo. Nature 416, 535–539.
14 Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG,
Yang A, Gallagher M and Ashe KH (2006) A specific
amyloid-beta protein assembly in the brain impairs
memory. Nature 440, 352–357.
1244 FEBS Letters 591 (2017) 1236–1246 ª 2017 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of
European Biochemical Societies
Specific Ab oligomer structures disrupt long-term memory L. Ford et al.
15 Millucci L, Raggiaschi R, Franceschini D, Terstappen
G and Santucci A (2009) Rapid aggregation and
assembly in aqueous solution of A beta (25–35) peptide.
J Biosci 34, 293–303.
16 Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T,
Condron MM, Bitan G, Teplow DB, Shea JE, Ruotolo
BT, Robinson CV et al. (2009) Amyloid-b protein
oligomerization and the importance of tetramers and
dodecamers in the aetiology of Alzheimer’s disease. Nat
Chem 4, 326–331.
17 O’Nuallain B, Freir DB, Nicoll AJ, Risse E,
Ferguson N, Herron CE, Collinge J and Walsh DM
(2010) Amyloid beta-protein dimers rapidly form
stable synaptotoxic protofibrils. J Neurosci 30, 14411–
14419.
18 Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu
C, Sherman MA, Lesne S, LaDu MJ, Walsh DM, Ashe
KH et al. (2011) Cognitive effects of cell-derived and
synthetically derived A beta oligomers. Neurobiol Aging
32, 1784–1794.
19 McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith
MJ, Vbeyreuther K, Bush AI and Masters CL (1999)
Soluble pool of A beta amyloid as a determinant of
severity of neurodegeneration in Alzheimer’s disease.
Ann Neurol 46, 860–866.
20 Hepler RW, Grimm KM, Nahas DD, Breese R,
Dobson EC, Acton P, Keller PM, Yeager M, Wang H,
Shughrue P et al. (2006) Solution state characterization
of amyloid beta-derived diffusible ligands. Biochemistry
45, 15157–15167.
21 Selkoe DJ (2002) Alzheimer’s disease is a synaptic
failure. Science 298, 789–791.
22 Finch CE and Sapolsky RM (1999) The evolution of
Alzheimer disease, the reproductive schedule, and apoE
isoforms. Neurobiol Aging 20, 407–428.
23 Tharp WG and Sarkar IN (2013) Origins of amyloid-
beta. BMC Genom 14, 290.
24 Prussing K, Voigt A and Schulz J (2013) Drosophila
melanogaster as a model organism for Alzheimer’s
disease. Mol Neurodegener 8, 25.
25 Lublin AL and Link CD (2013) Alzheimer’s disease
drug discovery: in vivo screening using Caenorhabditis
elegans as a model for beta-amyloid peptide-induced
toxicity. Drug Discov Today Technol 10, 115–119.
26 Rosen DR, Martinmorris L, Luo LQ and White K
(1989) A Drosophila gene encoding a protein resembling
the human beta-amyloid protein-precursor. Proc Natl
Acad Sci USA 86, 2478–2482.
27 Allinson TMJ, Parkin ET, Turner AJ and Hooper NM
(2003) ADAMs family members as amyloid precursor
protein alpha-secretases. J Neurosci Res 74, 342–352.
28 Boulianne GL, Livne-Bar I, Humphreys JM, Liang Y,
Lin C, Rogaev E and St George-Hyslop P (1997)
Cloning and characterization of the Drosophila
presenilin homologue. NeuroReport 8, 1025–1029.
29 Francis R, McGrath G, Zhang J, Ruddy DA, Sym M,
Apfeld J, Nicoll M, Maxwell M, Hai B, Ellis MC et al.
(2002) aph-1 and pen-2 are required for notch pathway
signaling, gamma-secretase cleavage of beta APP, and
presenilin protein accumulation. Dev Cell 3, 85–97.
30 Hong CS and Koo EH (1997) Isolation and
characterization of Drosophila presenilin homolog.
NeuroReport 8, 665–668.
31 Fossgreen A, Bruckner B, Czech C, Masters C,
Beyreuther K and Paro R (1998) Transgenic Drosophila
expressing human amyloid precursor protein show
gamma-secretase activity and a blistered-wing
phenotype. Proc Natl Acad Sci USA 95, 13703–13708.
32 Greeve I, Kretzschmar D, Tschape JA, Beyin A,
Brellinger C, Schweizer M, Nitsch RM and Reifegerste
R (2004) Age-dependent neurodegeneration and
Alzheimer-amyloid plaque formation in transgenic
Drosophila. J Neurosci 24, 3899–3906.
33 Moroz LL and Kohn AB (2010) Do different neurons
age differently? Direct genome-wide analysis of aging in
single identified cholinergic neurons. Front Aging
Neurosci 2, 2.
34 Bailey CH, Kandel ER and Harris KM (2015)
Structural components of synaptic plasticity and
memory consolidation. Cold Spring Harb Perspect Biol
7, a021758.
35 Schacher S, Castellucci VF and Kandel ER (1988)
cAMP evokes long-term facilitation in Aplysia sensory
neurons that requires new protein synthesis. Science
240, 1667–1669.
36 Dale N, Schacher S and Kandel ER (1988) Long-term
facilitation in Aplysia involves increase in transmitter
release. Science 239, 282–285.
37 Montarolo PG, Goelet P, Castellucci VF, Morgan J,
Kandel ER and Schacher S (1986) A critical period for
macromolecular synthesis in long-term heterosynaptic
facilitation in Aplysia. Science 234, 1249–1254.
38 Brunelli M, Castellucci V and Kandel ER (1976)
Synaptic facilitation and behavioral sensitization in
Aplysia: possible role of serotonin and cyclic AMP.
Science 194, 1178–1181.
39 Carew TJ and Kandel ER (1973) Acquisition and
retention of long-term habituation in Aplysia:
correlation of behavioral and cellular processes. Science
182, 1158–1160.
40 Byrne J, Hochner B and Kemenes G (2017) Cellular
and molecular mechanisms of memory in molluscs. In
Learning and Memory: A Comprehensive Reference
(Byrne J, ed.) I. Mechanisms of Memory (Sara S, ed.),
pp. 133–148. Elsevier, Cambridge, UK.
41 Samarova EI, Bravarenko NI, Korshunova TA,
Gulyaeva NV, Palotas A and Balaban PM (2005)
Effect of beta-amyloid peptide on behavior and
synaptic plasticity in terrestrial snail. Brain Res Bull 67,
40–45.
1245FEBS Letters 591 (2017) 1236–1246 ª 2017 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of
European Biochemical Societies
L. Ford et al. Specific Ab oligomer structures disrupt long-term memory
42 Ford L, Crossley M, Williams T, Thorpe JR, Serpell
LC and Kemenes G (2015) Effects of Ab exposure on
long-term associative memory and its neuronal
mechanisms in a defined neuronal network. Sci Rep 5,
10614.
43 Broersen K, Jonckheere W, Rozneski J, Vandersteen
A, Pauwels K, Pastore A, Rousseau F and
Schymkowitz J (2011) A standardized and
biocompatible preparation of aggregate-free amyloid
beta peptide for biophysical and biological studies
of Alzheimer’s disease. Protein Eng Des Sel 24,
743–750.
44 Soura V, Stewart-Parker M, Williams TL, Ratnayaka
A, Atherton J, Gorringe K, Tuffin J, Darwent E,
Rambaran R, Klein W et al. (2012) Visualization of co-
localization in A beta 42-administered neuroblastoma
cells reveals lysosome damage and autophagosome
accumulation related to cell death. Biochem J 441, 579–
590.
45 Kemenes I, Straub VA, Nikitin ES, Staras K, O’Shea
M, Kemenes G and Benjamin PR (2006) Role of
delayed nonsynaptic neuronal plasticity in long-term
associative memory. Curr Biol 16, 1269–1279.
46 Watson SN, Risling TE, Hermann PM andWilderingWC
(2012) Failure of delayed nonsynaptic neuronal plasticity
underlies age-associated long-term associative memory
impairment. BMCNeurosci 103, 103.
47 Marshall KE, Vadukul DM, Dahal L, Theisen A,
Fowler MW, Al-Hilaly Y, Ford L, Kemenes G, Day IJ,
Staras K et al. (2016) A critical role for the self-
assembly of amyloid-beta 1-42 in neurodegeneration.
Sci Rep 6, 30182.
48 Benjamin PR and Winlow W (1981) The distribution of
three wide-acting synaptic inputs to identified neurons
in the isolated brain of Lymnaea. Comp Biochem
Physiol 70, 293–307.
49 Williams TL, Day IJ and Serpell LC (2010) The
effect of Alzheimer’s Ab aggregation state on the
permeation of biomimetic lipid vesicles. Langmuir 26,
17260–17268.
50 McDonald JM, Cairns NJ, Taylor-Reinwald L,
Holtzman D and Walsh DM (2012) The levels of
water-soluble and triton-soluble A beta are increased in
Alzheimer’s disease brain. Brain Res 1450, 138–147.
51 Kemenes I, O’Shea M and Benjamin PR (2011)
Different circuit and monoamine mechanisms
consolidate long-term memory in aversive and reward
classical conditioning. Eur J Neurosci 33, 143–152.
52 Naskar S, Wan H and Kemenes G (2014) pT305-
CaMKII stabilizes a learning-induced increase in
AMPA receptors for ongoing memory consolidation
after classical conditioning. Nat Commun 5, 3967.
53 Nikitin ES, Vavoulis DV, Kemenes I, Marra V, Pirger
Z, Michel M, Feng J, O’Shea M, Benjamin PR and
Kemenes G (2008) Persistent sodium current is a
nonsynaptic substrate for long-term associative
memory. Curr Biol 18, 1221–1226.
54 Yeoman MS, Pieneman AW, Ferguson GP, Termaat A
and Benjamin PR (1994) Modulatory role for the
serotonergic cerebral giant-cells in the feeding system of
the snail, Lymnaea. 1. Fine wire recording in the intact
animal and pharmacology. J Neurophysiol 72,
1357–1371.
55 Takadera T, Sakura N, Mohri T and Hashimoto T
(1993) Toxic effect of a beta-amyloid peptide (beta-22-
35) on the hippocampal neuron and its prevention.
Neurosci Lett 161, 41–44.
56 Pike CJ, Burdick D, Walencewicz AJ, Glabe CG and
Cotman CW (1993) Neurodegeneration induced by
beta-amyloid peptides in vitro- the role of peptide
assembly state. J Neurosci 13, 1676–1687.
57 Williams TL and Serpell LC (2011) Membrane and
surface interactions of Alzheimer’s A beta peptide –
insights into the mechanism of cytotoxicity. FEBS J
278, 3905–3917.
58 Borlikova GG, Trejo M, Mably AJ, Mc Donald JM,
Sala Frigerio C, Regan CM, Murphy KJ, Masliah E
and Walsh DM (2013) Alzheimer brain-derived
amyloid beta-protein impairs synaptic remodeling and
memory consolidation. Neurobiol Aging 34,
1315–1327.
59 Klyubin I, Ondrejcak T, Hayes J, Cullen WK, Mably
AJ, Walsh DM and Rowan MJ (2014)
Neurotransmitter receptor and time dependence of the
synaptic plasticity disrupting actions of Alzheimer’s
disease A beta in vivo. Philos Trans R Soc Lond B Biol
Sci 369, 20130147.
60 Freir DB, Fedriani R, Scully D, Smith IM, Selkoe DJ,
Walsh DM and Regan CM (2011) A beta oligomers
inhibit synapse remodelling necessary for memory
consolidation. Neurobiol Aging 32, 2211–2218.
61 Casadio A, Martin KC, Giustetto M, Zhu H, Chen M,
Bartsch D, Bailey CH and Kandel ER (1999) A
transient, neuron-wide form of CREB-mediated long-
term facilitation can be stabilized at specific synapses
by local protein synthesis. Cell 99, 221–237.
Supporting information
Additional Supporting Information may be found
online in the supporting information tab for this
article:
Fig. S1. Solvent-prepared Ab 25–35 does not affect
certain intrinsic neuronal properties.
1246 FEBS Letters 591 (2017) 1236–1246 ª 2017 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of
European Biochemical Societies
Specific Ab oligomer structures disrupt long-term memory L. Ford et al.
